Bio-XL
Developing biopharma solutions to undertreated medical needs
ABOUT US
Bio-XL develops biopharma solutions for undertreated medical needs through innovative research and technology.
Bio-XL develops its projects from discovery to clinical stage.
Each project incorporates into a new company for further development and commercialization.
Bio-XL operates as a hub in its facility, which is located in Israel.
Our Products
NES Pharma
Neurodegenerative diseases treatment
Despite intensive clinical development, there are no available effective drug treatments for neurodegenerative diseases (i.e Alzheimers and others).
NES Pharma is developing a combination drug aimed at slowing disease progression and delaying the onset of cognitive symptoms and disability. This treatment is designed for individuals diagnosed with mild cognitive impairment (MCI) who are at high risk of developing dementia. Its goal is to help sustain a relatively good quality of life over the long term (more than 10 years).
To learn more about Nes Pharma click here
The technology is licensed to Bio-XL.
CeaseCancer
Universal anti-cancer drug, alternative to chemotherapy
Clinical advancements have led to effective treatments for most cancer types. However, despite reluctance, chemotherapy often remains the primary drug therapy in many cases.
CeaseCancer, with its unique MoA, strong safety profile, and ability to target a wide range of cancer types and stages, offers the potential to replace chemotherapy or, when used in combination, to reduce doses and minimize adverse effects.
Initially, CeaseCancer is intended for the treatment of TNBC and PDAC, where survival rates are low and chemotherapy is often the only available option.
To learn more about CeaseCancer click here
The technology is licensed to Bio-XL.
CancerPredict
Diagnostic test for improved cancer prognosis
Current prediction models do not reliably assess cancer development risk.
Accurate prognosis of breast cancer enables prophylactic treatments, improved treatments outcome, increased survival rate and improved quality of life
The test (addition to the current screening program) uses a digital pathology method and big-data system assisted by AI.
To learn more about CancerPredict click here
The technology is licensed to Bio-XL.
AMP-Bio
Treatment for antibiotic resistant bacteria
Antibiotic resistant bacteria pose a serious threat to the global healthcare system.
AMP-Bio develops antimicrobial-peptides (AMPs) for treating resistant bacteria, the treatment is anticipated to diminish the adverse effects on the microbiome of the patient.
To learn more about AMP-Bio click here
The technology is licensed to Bio-XL.
Marathon
Longevity treatment
Marathon develops a vehicle for safe administration in mitochondria replacement therapy (MRT).
To learn more about Marathon click here
The technology is licensed to Bio-XL.
Portfolio
Portfolio includes projects at various therapeutic fields and different stages of development.
